(Q47394886)

English

Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial

scientific article published on 13 November 2017

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/29146124

Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/29146124

circulatory system

1 reference

based on heuristic

inferred from title

4

object named as

Peter Libby

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

1

object named as

Paul M Ridker

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/29146124

6

object named as

Robert J Glynn

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/29146124

1 reference

ORCID Public Data File 2021

Jean G MacFadyen

2

object named as

Jean G MacFadyen

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/29146124

5

object named as

Tom Thuren

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/29146124

CANTOS Trial Group

7

object named as

CANTOS Trial Group

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/29146124

author name string

Brendan M Everett

3

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/29146124

language of work or name

0 references

publication date

13 November 2017

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/29146124

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/29146124

Inflammation, atherosclerosis, and coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2932814-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Inflammation in atherosclerosis: from pathophysiology to practice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2932814-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2932814-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2932814-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2932814-3

7 January 2021

based on heuristic

inferred from DOI database lookup

2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2932814-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Intensive versus moderate lipid lowering with statins after acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2932814-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2932814-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2932814-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2932814-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2932814-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2932814-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2932814-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2932814-3

7 January 2021

based on heuristic

inferred from DOI database lookup

C-reactive protein levels and outcomes after statin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2932814-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2932814-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2932814-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2932814-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Creating controversy where none exists: the important role of C-reactive protein in the CARE, AFCAPS/TexCAPS, PROVE IT, REVERSAL, A to Z, JUPITER, HEART PROTECTION, and ASCOT trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2932814-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2932814-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Therapeutic monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2932814-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Residual inflammatory risk: addressing the obverse side of the atherosclerosis prevention coin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2817%2932814-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(17)32814-3

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/29146124

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/29146124

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47394886&oldid=2155104762"